These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 17261742)

  • 1. Screening potential therapies: lessons learned from new paradigms used in Parkinson disease.
    Tilley BC; Galpern WR
    Stroke; 2007 Feb; 38(2 Suppl):800-3. PubMed ID: 17261742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs.
    Tilley BC; Palesch YY; Kieburtz K; Ravina B; Huang P; Elm JJ; Shannon K; Wooten GF; Tanner CM; Goetz GC;
    Neurology; 2006 Mar; 66(5):628-33. PubMed ID: 16534099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in drug development for Parkinson's disease: present status.
    Harikrishna Reddy D; Misra S; Medhi B
    Pharmacology; 2014; 93(5-6):260-71. PubMed ID: 25096413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials.
    Meissner W; Hill MP; Tison F; Gross CE; Bezard E
    Trends Pharmacol Sci; 2004 May; 25(5):249-53. PubMed ID: 15120490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs?
    Clarke CE
    Mov Disord; 2004 May; 19(5):491-8. PubMed ID: 15133811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of cognitive outcomes in early Parkinson disease patients: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience.
    Schneider JS; Elm JJ; Parashos SA; Ravina BM; Galpern WR;
    Parkinsonism Relat Disord; 2010 Sep; 16(8):507-12. PubMed ID: 20598621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of Functional Decline in Early Parkinson's Disease: NET-PD LS1 Cohort.
    Bega D; Kim S; Zhang Y; Elm J; Schneider J; Hauser R; Fraser A; Simuni T
    J Parkinsons Dis; 2015; 5(4):773-82. PubMed ID: 26639661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Neuroprotection in Parkinson's disease: analysis though group of experts' methodology].
    Linazasoro G; Sesar A; Valldeoriola F; Compta Y; Herrero MT; Martínez Castrillo JC; López Lozano JJ; Bergaretxe A; Vela L; Fernández JM; Castro A; Kulisevski J; Lezcano E; Vaamonde J; López Del Val J; Chacón J; Vivancos F; Luquin R; Aguilar M; Burguera JA; Salvador C; Menéndez Guisasola L; Catalán MJ; Mir P; Campos V; Grandas F; Mínguez A; Balaguer E; Yáñez R; Leiva C; García Ruiz P; Cubo E
    Neurologia; 2009 Mar; 24(2):113-24. PubMed ID: 19322690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2020.
    McFarthing K; Buff S; Rafaloff G; Dominey T; Wyse RK; Stott SRW
    J Parkinsons Dis; 2020; 10(3):757-774. PubMed ID: 32741777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of early Parkinson's disease. Part 2.
    Simuni T; Lyons KE; Pahwa R; Hauser RA; Comella C; Elmer L; Weintraub D
    Eur Neurol; 2009; 61(4):206-15. PubMed ID: 19176961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignant melanoma in early-treated Parkinson's disease: the NET-PD trial.
    Constantinescu R; Elm J; Auinger P; Sharma S; Augustine EF; Khadim L; Kieburtz K;
    Mov Disord; 2014 Feb; 29(2):263-5. PubMed ID: 24323565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NINDS clinical trials in stroke: lessons learned and future directions.
    Marler JR
    Stroke; 2007 Dec; 38(12):3302-7. PubMed ID: 17962606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What's in the pipeline for the treatment of Parkinson's disease?
    Sommer DB; Stacy MA
    Expert Rev Neurother; 2008 Dec; 8(12):1829-39. PubMed ID: 19086879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Self-reported adherence versus pill count in Parkinson's disease: the NET-PD experience.
    Elm JJ; Kamp C; Tilley BC; Guimaraes P; Fraser D; Deppen P; Brocht A; Weaver C; Bennett S;
    Mov Disord; 2007 Apr; 22(6):822-7. PubMed ID: 17357141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1.
    Elm JJ;
    Mov Disord; 2012 Oct; 27(12):1513-21. PubMed ID: 23079770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ALS lessons learned from other neurological diseases. Parkinson's disease.
    Fahn S
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():26-30. PubMed ID: 15512865
    [No Abstract]   [Full Text] [Related]  

  • 18. New treatments for the motor symptoms of Parkinson's disease.
    Vijverman AC; Fox SH
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):761-77. PubMed ID: 25318835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis.
    Dunkel P; Chai CL; Sperlágh B; Huleatt PB; Mátyus P
    Expert Opin Investig Drugs; 2012 Sep; 21(9):1267-308. PubMed ID: 22741814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.